ABOUT2022-07-18T12:54:31+00:00

A Bit About Us

We focus on developing nano-therapeutics for the prevention and treatment of skin infections using the power of nanotechnology


Our goal is to enable a future free of antibiotic resistance through innovation and discovery of a novel class of nanotechnology-based antimicrobials


Prasanna Gore, PhD

Cofounder and CEO

Know More

David Medina Cruz, PhD

Cofounder and Head of R&D

Know More

Thomas Webster, PhD

Cofounder and Chief Scientific Officer

Know More

Mahesh Sambasivam, PhD

Chief Business Officer

Know More

Whitney Herchek, MS

Head of Market Access

Know More

Our Partners and Collaborators

Frequently Asked Questions

What is SynCell?2020-08-16T11:02:44+00:00

SynCell Biotechnology Inc. is a biotechnology startup company based in the U.S. focused on developing microbially-synthesized nanomaterials with biomedical applications. 

What is our mission?2022-06-14T16:51:51+00:00
Our mission is to “develop reliable and sustainable therapeutics for the prevention and treatment of antibiotic resistant infections using the power of bacterially-derived nanoparticles.”
What are our principles and values?2022-06-14T16:53:13+00:00
Our core values are built over three foundational principles that guide us at every step of our mission:
  1. Quality in innovation. We seek to bring the best of the intersection between microbiology and nanotechnology in the shape of solutions with great potential to tackle the most compelling healthcare concerns.
  2. The greenway. We seek to incorporate the principles of Green Nanotechnology at every step of our technology process that relies on cost-effective and environmentally-friendly approaches.
  3. The value of people. Above all, we will not be able to achieve what we aim for without the dedication of our people. Our team members are our greatest asset!
What is the problem we are trying to solve?2022-06-14T16:57:59+00:00
One of the biggest challenges in healthcare today is the rise and development of Anti-Microbial Resistance to antibiotics (AMR).
  • Each year in the United States, nearly 3 million people get an antibiotic-resistant infection leading to more than 35,000 deaths and a staggering $55 billion in healthcare costs.
  • Fighting this healthcare threat is a public health priority and our mission.
Why are we doing this?2022-06-14T16:53:46+00:00
Every day someone loses a relative or close friend to AMR (Anti-Microbial Resistance) when the antibiotic treatments fail due to the development of resistance. It is our moment to step up and say “no more”. We at SynCell are committed to seeking a future where antibiotic failure will not leave us without options. We are working on producing alternative solution to fight AMR. 
How are we tackling this problem?2022-06-14T16:55:02+00:00
At SynCell, we believe that the solution towards AMR is not in the form of traditional antibiotics.
  • We provide an innovative solution that uses the bacteria itself to fight the problem of antibiotic resistance.
  • By understanding the mechanisms of key biochemical processes in prokaryotic cells, we use bacteria as biofactories of nanomaterials without introducing any genetic manipulation in the organisms.
  • Once produced, the nanomaterials are purified and employed as either sole antimicrobials or key components in combinatorial medical devices.
What is our target market?2022-06-14T16:58:29+00:00
Our initial portfolio of products is composed by SYN-BAC, a family of antimicrobial dressings to treat open wounds that are either prone to infections or are already infected with bacteria. 
Go to Top